MARKET

ACTU

ACTU

Actuate Therapeutics Inc
NASDAQ
1.960
+0.010
+0.51%
After Hours: 1.960 0 0.00% 16:10 06/25 EDT
OPEN
1.960
PREV CLOSE
1.950
HIGH
2.010
LOW
1.920
VOLUME
90.33K
TURNOVER
--
52 WEEK HIGH
9.22
52 WEEK LOW
1.580
MARKET CAP
46.89M
P/E (TTM)
-1.9836
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACTU last week (0615-0619)?
Weekly Report · 4d ago
Weekly Report: what happened at ACTU last week (0608-0612)?
Weekly Report · 06/15 09:26
Buy Rating Reaffirmed on Elraglusib Momentum and External Validation; $15 ACTU Price Target Maintained
TipRanks · 06/10 10:25
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 06/09 21:06
Actuate Therapeutics' Elraglusib To Be Evaluated In BEACON2 Clinical Study To Identify, Proceed To Treat Children With Relapsed, Refractory Neuroblastoma
Benzinga · 06/09 11:48
ACTUATE THERAPEUTICS’ ELRAGLUSIB SELECTED FOR EVALUATION IN BEACON2 TRIAL FOR HIGH-RISK PEDIATRIC NEUROBLASTOMA
Reuters · 06/09 11:45
Actuate says elraglusib enters BEACON2 Phase 1/2 trial in relapsed pediatric neuroblastoma
PUBT · 06/09 11:45
Weekly Report: what happened at ACTU last week (0601-0605)?
Weekly Report · 06/08 09:25
More
About ACTU
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.

Webull offers Actuate Therapeutics Inc stock information, including NASDAQ: ACTU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACTU stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACTU stock methods without spending real money on the virtual paper trading platform.